How Does Flecainide Work? Mechanism of Action Explained in Plain English

When your cardiologist prescribes flecainide, they're putting a powerful molecular brake on your heart's electrical system. Understanding how it works — even at a basic level — can help you understand why it's effective, why it requires careful monitoring, and why it can't be used by everyone.

First: How Does the Heart's Electrical System Work?

Your heart beats because of a carefully timed series of electrical impulses. Each beat starts at the sinoatrial (SA) node — the heart's natural pacemaker — which sends an electrical signal that travels through specialized conduction pathways to coordinate the contraction of the heart chambers.

This electrical signal is generated by ions moving in and out of heart muscle cells through specialized protein channels in the cell membrane. The most critical channels for generating the heartbeat signal are fast sodium (Na+) channels. When these channels open, sodium floods into the cell, triggering the electrical event (called the action potential) that propagates through the heart.

What Happens When the Electrical System Misfires?

Arrhythmias occur when this electrical system misfires — either starting in the wrong place, traveling via an abnormal pathway, going too fast, or circling in loops that don't terminate naturally. In atrial fibrillation (AFib), for example, chaotic electrical signals in the atria fire rapidly and irregularly, making the upper chambers quiver instead of pumping effectively.

In paroxysmal SVT, the signal travels in a reentrant loop — going around and around through the AV node or via an accessory pathway, producing a rapid heart rate that can feel like a suddenly racing heart or pounding chest.

How Flecainide Stops Arrhythmias: Sodium Channel Blockade

Flecainide works by blocking fast sodium channels in heart cells. By partially blocking these channels, it reduces the speed and amplitude of the electrical impulse traveling through heart muscle. This has several effects:

• Slows conduction velocity: The electrical signal travels more slowly through the heart tissue, especially through the His-Purkinje system (the specialized fast-conduction fibers). On an ECG, this shows up as a widened QRS complex.
• Disrupts reentrant circuits: Many arrhythmias depend on rapid reentrant circuits — electrical loops that keep firing. Slowing conduction breaks these loops by introducing a conduction delay that terminates the circuit.
• Reduces maximal upstroke velocity (Vmax): The "steepness" of the electrical signal's rise in each cell is reduced, decreasing excitability and making it harder for abnormal signals to propagate.
• Minimal effect on QT interval: Unlike Class III antiarrhythmics (such as amiodarone or sotalol), flecainide primarily affects the sodium channel phase of the action potential and has minimal effect on the QT interval — the period of repolarization. This means it causes less risk of torsade de pointes than Class III agents in patients with normal hearts.

Why Is Flecainide Called a "Class IC" Drug?

Antiarrhythmic drugs are classified by the Singh-Vaughan Williams system based on their mechanism. Class I drugs all block sodium channels, but they differ in how tightly and for how long they bind:

• Class IA (quinidine, procainamide): Moderate sodium channel binding; also prolong QT
• Class IB (lidocaine, mexiletine): Weak, fast-dissociating binding; mainly effective for ventricular arrhythmias
• Class IC (flecainide, propafenone): Strongest and slowest-dissociating sodium channel block; most potent conduction slowing; minimal effect on repolarization (QT)

Class IC drugs have the most potent conduction-slowing effect of all sodium channel blockers, which makes them effective but also potentially dangerous in the wrong patients.

Why Can't Everyone Take Flecainide? (The Structural Heart Disease Problem)

Here's where flecainide's mechanism creates its most important limitation. By slowing conduction throughout the heart, flecainide can — paradoxically — make things worse in hearts with damaged or diseased tissue.

In a structurally normal heart, slowing conduction uniformly breaks reentrant circuits without creating new problems. But in a heart with scar tissue from a prior heart attack, the scar creates areas of abnormal, slow conduction already. Adding a sodium channel blocker on top of these slow-conduction zones can create the conditions for dangerous, sustained ventricular arrhythmias.

This is exactly what the CAST trial showed in 1989: patients with recent MI and non-life-threatening VAs had significantly higher death rates when treated with flecainide (5.1%) compared to placebo (2.3%). The drug was stopping arrhythmias but creating worse ones in these vulnerable patients.

Why Flecainide Also Has a Negative Inotropic Effect

Beyond its electrical effects, flecainide also has a negative inotropic effect — it slightly reduces the strength of the heart muscle's contraction. In patients with already impaired heart function (reduced ejection fraction or heart failure), this can worsen cardiac output. This is another reason why flecainide is avoided in patients with heart failure.

The Pill-in-the-Pocket Strategy: Mechanism at Work

For patients with infrequent paroxysmal AFib, cardiologists sometimes use flecainide as a "pill-in-the-pocket" — a single large dose taken at the onset of symptoms to chemically cardiovert the arrhythmia. This works because a high acute dose creates intense sodium channel blockade that terminates the reentrant AFib circuit, usually within 1–3 hours.

This approach is only appropriate for patients who have been pre-evaluated in the hospital, confirmed to have no underlying structural heart disease, and confirmed not to have accelerated AV conduction with the drug (which would need to be managed with concurrent beta-blockers or calcium channel blockers).

What Does Flecainide Show on an ECG?

Flecainide produces characteristic dose-dependent changes on the ECG:

• Prolonged PR interval: Reflects slowed AV nodal conduction
• Widened QRS complex: The most characteristic finding; reflects slowed His-Purkinje conduction. This is expected and not dangerous at therapeutic doses.

These ECG changes are used to monitor whether your dose is in the therapeutic range and whether the drug is affecting conduction appropriately. Your cardiologist will check an ECG after 5 doses at each new dose level.

For a practical overview of how to take flecainide, dosage information, and availability tips, see our complete flecainide patient guide.